Literature DB >> 18818322

Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc.

Xuefeng Liu1, Aleksandra Dakic, Renxiang Chen, Gary L Disbrow, Yiyu Zhang, Yuhai Dai, Richard Schlegel.   

Abstract

The high-risk human papillomaviruses (HPVs) are the causative agents of nearly all cervical cancers and are etiologically linked to additional human cancers, including those of anal, oral, and laryngeal origin. The main transforming genes of the high-risk HPVs are E6 and E7. E6, in addition to its role in p53 degradation, induces hTERT mRNA transcription in genital keratinocytes via interactions with Myc protein, thereby increasing cellular telomerase activity. While the HPV type 16 E6 and E7 genes efficiently immortalize human keratinocytes, they appear to only prolong the life span of human fibroblasts. To examine the molecular basis for this cell-type dependency, we examined the correlation between the ability of E6 to transactivate endogenous and exogenous hTERT promoters and to immortalize genital keratinocytes and fibroblasts. Confirming earlier studies, the E6 and E7 genes were incapable of immortalizing human fibroblasts but did delay senescence. Despite the lack of immortalization, E6 was functional in the fibroblasts, mediating p53 degradation and strongly transactivating an exogenous hTERT promoter. However, E6 failed to transactivate the endogenous hTERT promoter. Coordinately with this failure, we observed that Myc protein was not associated with the endogenous hTERT promoter, most likely due to the extremely low level of Myc expression in these cells and/or to differences in chromatin structure, in contrast with hTERT promoters that we found to be activated by E6 (i.e., the endogenous hTERT promoter in primary keratinoctyes and the exogenous hTERT core promoter in fibroblasts), where Myc is associated with the promoter in either a quiescent or an E6-induced state. These findings are consistent with those of our previous studies on mutagenesis and the knockdown of small interfering RNA, which demonstrated a requirement for Myc in the induction of the hTERT promoter by E6 and suggested that occupancy of the promoter by Myc determines the responsiveness of E6 and the downstream induction of telomerase and cell immortalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818322      PMCID: PMC2583678          DOI: 10.1128/JVI.01318-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  The Myc/Max/Mad network and the transcriptional control of cell behavior.

Authors:  C Grandori; S M Cowley; L P James; R N Eisenman
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

Review 2.  Function and regulation of the transcription factors of the Myc/Max/Mad network.

Authors:  B Lüscher
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

3.  Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites.

Authors:  S T Oh; S Kyo; L A Laimins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Telomerase catalytic subunit homologs from fission yeast and human.

Authors:  T M Nakamura; G B Morin; K B Chapman; S L Weinrich; W H Andrews; J Lingner; C B Harley; T R Cech
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

5.  E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc.

Authors:  L Gewin; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 6.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

7.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

8.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

9.  Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein.

Authors:  T Veldman; I Horikawa; J C Barrett; R Schlegel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

View more
  28 in total

1.  P16/p53 expression and telomerase activity in immortalized human dental pulp cells.

Authors:  Obi Egbuniwe; Bernadine D Idowu; Juan M Funes; Andrew D Grant; Tara Renton; Lucy Di Silvio
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  HPV E6 protein interacts physically and functionally with the cellular telomerase complex.

Authors:  Xuefeng Liu; Aleksandra Dakic; Yiyu Zhang; Yuhai Dai; Renxiang Chen; Richard Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-20       Impact factor: 11.205

3.  Human telomerase reverse transcriptase regulates vascular endothelial growth factor expression via human papillomavirus oncogene E7 in HPV-18-positive cervical cancer cells.

Authors:  Fang Li; Jinquan Cui
Journal:  Med Oncol       Date:  2015-06-12       Impact factor: 3.064

4.  Telomerase expression in amyotrophic lateral sclerosis (ALS) patients.

Authors:  Bruna De Felice; Anna Annunziata; Giuseppe Fiorentino; Francesco Manfellotto; Raffaella D'Alessandro; Rita Marino; Marco Borra; Elio Biffali
Journal:  J Hum Genet       Date:  2014-08-21       Impact factor: 3.172

Review 5.  Regulation of cellular miRNA expression by human papillomaviruses.

Authors:  Zhi-Ming Zheng; Xiaohong Wang
Journal:  Biochim Biophys Acta       Date:  2011-05-17

6.  O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis.

Authors:  Qinghua Zeng; Rui-Xun Zhao; Jianfeng Chen; Yining Li; Xiang-Dong Li; Xiao-Long Liu; Wei-Ming Zhang; Cheng-Shi Quan; Yi-Shu Wang; Ying-Xian Zhai; Jian-Wei Wang; Mariam Youssef; Rutao Cui; Jiyong Liang; Nicholas Genovese; Louise T Chow; Yu-Lin Li; Zhi-Xiang Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

7.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

8.  Tissue specificity of a human mitochondrial disease: differentiation-enhanced mis-splicing of the Fe-S scaffold gene ISCU renders patient cells more sensitive to oxidative stress in ISCU myopathy.

Authors:  Daniel R Crooks; Suh Young Jeong; Wing-Hang Tong; Manik C Ghosh; Hayden Olivierre; Ronald G Haller; Tracey A Rouault
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 9.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

10.  TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.

Authors:  Vilvanathan Vinothkumar; Ganesan Arunkumar; Sundaramoorthy Revathidevi; Kanagaraj Arun; Mayakannan Manikandan; Arunagiri Kuha Deva Magendhra Rao; Kottayasamy Seenivasagam Rajkumar; Chandrasekar Ajay; Ramamurthy Rajaraman; Rajendren Ramani; Avaniyapuram Kannan Murugan; Arasambattu Kannan Munirajan
Journal:  Tumour Biol       Date:  2015-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.